

The HEV Ventilator

Jan Buytaert^a, Paula Collins^{a,1}, Adam Abed Abud^{a,b}, Phil Allport^c, Antonio Pazos Álvarez^d, Kazuyoshi Akiba^e, Oscar Augusto de Aguiar Francisco^{a,q}, Aurelio Bay^f, Florian Bernard^f, Sophie Baron^a, Claudia Bertella^a, Josef X. Brunner^g, Themis Bowcock^b, Martine Buytaert-De Jode¹, Wiktor Byczynski^{a,h}, Ricardo De Carvalhoⁱ, Victor Coco^a, Ruth Collins^j, Nikola Dikić^a, Nicolas Dousse¹, Bruce Dowd^k, Raphael Dumps^a, Paolo Durante^a, Walid Fadel^a, Stephen Farry^b, Antonio Fernández Prieto^d, Gordon Flynn^{k,l}, Vinicius Franco Lima^b, Raymond Frei^f, Abraham Gallas Torreira^d, Roberto Guida^a, Karol Hennessy^b, Andre Henriques^a, David Hutchcroft^b, Stefan Ilic^m, Aleksandar Jevtic^m, Christian Joram^a, Kacper Kapusniak^a, Edgar Lemos Cid^d, Jana Lindnerⁿ, Rolf Lindner^a, Marko Milovanovic^{o,a}, Sylvain Mico^a, Johan Morant^a, Michel Morel^a, Georg Männel^p, Donal Murray^q, Irina Nasteva^r, Niko Neufeld^a, Igor Neuhold^a, Francisco Pardo-Sobrinho López^s, Eliseo Pérez Trigo^d, Gonzalo Pichel Jallas^t, Edyta Pilorz^a, Lise Piquilloud^f, Xavier Pons^a, David Reiner^u, Carl Roosens^v, Philipp Rostalski^p, Freek Sanders^a, Eric Saucet¹, Burkhard Schmidt^a, Patrick Schoetker^t, Rainer Schwemmer^a, Heinrich Schindler^a, Archana Sharma^a, Christophe Sigaud^a, Peter Svihra^q, Jan van Leemput^v, Laurence Vignaux^w, Francois Vasey^a, Hamish Wootton^{x,y}, and Ken Wyllie^a

^aEuropean Organization for Nuclear Research (CERN), CH-1211 Genève 23, Switzerland; ^bOliver Lodge Laboratory, University of Liverpool, Liverpool, L69 7ZE, United Kingdom; ^cParticle Physics Group, School of Physics and Astronomy, University of Birmingham, B15 2TT, United Kingdom; ^dInstituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, 15782 Galicia, Spain; ^eNikhef National Institute for Subatomic Physics, Amsterdam, 1098 XG, Netherlands; ^fInstitute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland; ^gNeosim AG, CH-7000 Chur, Switzerland; ^hTadeusz Kosciuszko Cracow University of Technology, 31-155 Cracow, Poland; ⁱHôpitaux Universitaires de Genève, 1205 Genève, Switzerland; ^jDepartment of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA; ^kPrince of Wales Hospital, New South Wales, NSW 2052, Australia; ^lUniversity of New South Wales, New South Wales, NSW 2052, Australia; ^mApplied Physics Laboratory, Faculty of Electronic Engineering, University of Niš, Aleksandra Medvedeva 14, Niš 18000, Serbia; ⁿUniversity of Applied Sciences Offenburg, 77652 Offenburg, Baden-Wuerttemberg, Germany; ^oDeutsches Elektronen-Synchrotron (DESY), Platanenallee 6, 15738 Zeuthen, Germany; ^pInstitute for Electrical Engineering in Medicine, University of Lübeck, 23562 Lübeck, Germany; ^qDepartment of Physics and Astronomy, University of Manchester, Manchester, M13 9PL, United Kingdom; ^rUniversidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, 21941-972, Brazil; ^sAnesthesiology-Reanimation and Pain Therapeutics Service, Lucus Augusti University Hospital, 27003 Lugo, Spain; ^tCentre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland; ^uJohn Curtin School of Medical Research, Canberra, ACT 2600, Australia; ^vGZA Hospitals, 2018 Antwerp, Belgium; ^wCardio-Respiratory Units, Hôpital de La Tour, 1217 Meyrin, Switzerland; ^xMonash Health, Melbourne, VIC 3168, Australia; ^yDandenong Hospital, Melbourne, VIC 3175, Australia

This manuscript was compiled on August 18, 2020

1 **HEV is a low-cost, versatile, high-quality ventilator, which has been**
2 **designed in response to the COVID-19 pandemic. The ventilator**
3 **is intended to be used both in and out of hospital intensive care**
4 **units, and for both invasive and non-invasive ventilation. The hard-**
5 **ware can be complemented with an external turbine for use in re-**
6 **gions where compressed air supplies are not reliably available. The**
7 **standard modes provided include PC-A/C (Pressure Assist Control),**
8 **PC-A/C-PRVC (Pressure Regulated Volume Control), PC-PSV (Pres-**
9 **sure Support Ventilation) and CPAP (Continuous Positive Airway**
10 **Pressure). HEV is designed to support remote training and post mar-**
11 **ket surveillance via a web interface and data logging to complement**
12 **the standard touch screen operation, making it suitable for a wide**
13 **range of geographical deployment. The HEV design places emphasis**
14 **on the quality of the pressure curves and the reactivity of the trigger,**
15 **delivering a global performance which will be applicable to ventila-**
16 **tor needs beyond the COVID-19 pandemic. This article describes the**
17 **conceptual design and presents the prototype units together with**
18 **their performance evaluation.**

COVID-19 | Mechanical Ventilator | Biomedical Engineering

1 **T**he worldwide community currently faces a shortage, es-
2 pecially in low and middle income settings, of medical
3 equipment to address the COVID-19 pandemic (1–4). In
4 particular this is the case for ventilators, which are needed
5 during COVID-19 related treatment both in the acute phase,
6 when invasive fully controlled ventilation is needed, and also
7 in the sub-acute phase during the weaning from mechanical
8 ventilation, which can last for an extended time period. The
9 pandemic has also drawn attention to the lack of ventilation
10 equipment in low and middle income countries. Globally, pneu-
11 monia is the most common infectious cause of death (5–7),
12 and the need for adequate respiratory equipment for treatment
13 and management of pneumonia patients will persist even as
14 the COVID-19 pandemic wanes.

A large number of proposals are already circulating for de-
vices which can be quickly manufactured cheaply and on large
scale (8). However, the designs of many of these devices limit
the ability to reach high quality performance and monitoring.
The HEV (High Energy particle physics Ventilator), first pro-
posed here (9) is intended to provide full functionality while
being capable of manufacture at relatively low cost. The design
is based on regulations and recommendations from MHRA
(Medicines and Healthcare products Regulatory Agency), EU,
AAMI and WHO (10–12). HEV has been developed by a
group of physicists and engineers affiliated to CERN and part-
ner institutes, reinforced by an international advisory body of
clinicians, with advice, collaboration and equipment provided
from local hospitals. The design and controls are based on
concepts routinely used in the context of High Energy Physics

Significance Statement

Pulmonary lung disease has a global impact as a major cause of morbidity. The COVID-19 pandemic presents new challenges for the scientific community that cross the boundaries of scientific expertise and need to be addressed with new interdisciplinary collaborations. In this article, we describe the development of a high-quality, low-cost ventilator to provide artificial support for lung function of patients using technologies developed by the particle physics community for pressure and gas regulation. In addition to providing functionality for COVID-19 management, in the long-term this collaboration provides novel tools for ventilator performance monitoring, remote training, and clinical support, as well as the possibility to develop new algorithms and techniques based on the HEV design.

²To whom correspondence should be addressed. E-mail: paula.collins@cern.ch



research and use functionality which has been developed over decades for this field. The advantage of this cross-disciplinary approach and open collaboration is that the highest quality of ventilator construction can be expected, while being able to incorporate novel ideas during the development.

1. Overview of HEV functionality

Patients affected by COVID-19 face serious issues of lung damage, and the ventilatory equipment must be able to deliver protective pressure controlled ventilation throughout situations of rapidly changing lung compliance as well as potential collapse and consolidation. In light of the prolonged recovery/weaning phases involved in COVID-19 critical care cases, the ventilator must also deliver pressure-assisted ventilation to be efficient for the ventilator weaning process. HEV* delivers as basic modes PC-A/C (Pressure Control – Assist Control) and PC-A/C-PRVC (Pressure Control – Assist Control – Pressure Regulated Volume Controlled), PC-PSV (Pressure Control – Pressure Supported Ventilation), and in addition CPAP (Continuous Positive Airway Pressure). The CPAP mode is included with the HEV modes in order to provide the widest range of support throughout COVID-19 treatment, and may be a crucial option for selection in low resource settings (13). For all modes, PEEP (Positive End-Expiratory Pressure) is provided, to support steady low positive pressure to the lungs to avoid alveolar collapse.

In all modes it is possible to measure the plateau pressure and intrinsic PEEP in order to provide clinical diagnoses and estimation of the patient static lung compliance or to detect AutoPEEP. This is achieved by allowing a manual operation of a pause time at the end of the inhalation phase of a few hundred milliseconds during which the valves are occluded, in order to accurately measure plateau alveolar pressure at zero flow. The intrinsic PEEP at the end of the exhale phase can be measured in the same way during the pre-inhale state.

2. HEV Conceptual Design




Fig. 1. Conceptual design of the HEV ventilator.

Central Pneumatic Unit. The HEV design, shown conceptually in Fig. 1, is based around a central buffer which pneumatically decouples the ventilator circuit into two independently functioning parts, for filling the buffer and supplying gas to the patient. The air and oxygen are supplied separately and passively mixed inside the buffer, which is filled to a target

pressure. Once this has been achieved, the buffer output valve is opened, initiating the respiratory cycle. The inhale valve is controlled by a PID (Proportional–Integral–Derivative) controller, which allows a stable delivery of pressure and a fine tuning of the pressure rise time. After the inhalation phase finishes, the exhale valve is opened for exhalation and the buffer is re-filled for the next breath cycle. For CPAP operation the input valves to the buffer are kept open and the PID valve is regulated to supply a constant level of pressure. The PID algorithm ensures that the system is robust against fluctuations in flow or gas supply pressure.

The buffer concept presents many operational advantages. In general, the separation of the fill and exhale cycle into two separate circuits makes the design, control and component selection more straightforward, and allows less expensive components to be selected. The initial step-down of the pressure between the supply and the patient introduces safety and robustness, and makes precise pressure control on the patient side of the circuit more readily accessible. The buffer volume also avoids that the O₂ and air delivery systems need to be able to handle the peak flow rates of up to 120 L/min needed in the inhale phase, and the patient air supply is protected. The mixing of the gases, which is provided inside the buffer with an turbulent flow mechanism, avoids the need to purchase an external gas blender. In addition the measurement of the O₂ concentration, which can be done by spying on the static gas volume, is an inherently more precise measurement than measuring on a gas stream. Should the design need to be adapted to a more extreme (very hot or very cold) environment, thermal control of the gas in the buffer is straightforward. In addition, the delivered tidal volume can be calculated from the pressure drops in the buffer, providing a precious monitoring cross-check in addition to the standard tidal volume measurement, reinforcing the safety of the design.





Fig. 2. Schematic of the pneumatic part of the HEV system.

A schematic of the central pneumatic part of the system is shown in Fig. 2. This diagram highlights how pure oxygen and air are injected separately into the buffer by using two different valves. To achieve a good mix via turbulent air flow, a tube is inserted into the tank from the air side, taking air to be injected close to the oxygen injection point. The oxygen levels can be mixed from 21 to 100 percent, and the oxygen fraction is measured with zirconia sensors inserted after the oxygen tank which are reliable, inexpensive and readily available. The sensors are installed after a bypass, which enables them to be independent of the patient supply and to operate with low

*<https://hev.web.cern.ch>

116 flow of gas.

117 **Alternative air supply and accessories.** The HEV collabora- 154
118 tion has designed an alternative to the compressed air supply 155
119 available in hospitals. The major requirement is that the 156
120 system should be able to fill the HEV buffer in less than 157
121 one second. It consists of a small and transportable system, 158
122 based on miniature turbine blowers installed in series. The air 159
123 reaches thermal equilibrium with the environment via trans- 160
124 port in a corrugated pipe before delivery to the ventilator via 161
125 a HEPA (high-efficiency particulate air) filter. For increased 162
126 independence from the hospital setting, an external battery 163
127 can be included to power the turbine and the HEV together; 164
128 good performance has been obtained from an option based on 165
129 the e-bike battery market. The design of the prototype with 166
130 a photograph of the constructed turbine is shown in Fig. 3. 167



131 **Fig. 3.** Turbine system proposed as an alternative to the compressed air supply. The 154
132 system is divided into two parts; the top part containing the turbines, the bottom 155
133 containing the corrugated pipe, the thermal and pressure sensors and the outlet 156
134 connector. Mounted on the left side of the box are the air filter, the power supply and 157
135 the box containing the controller. The blue box on the right provides an enclosure for 158
136 the optional battery system. 159

137 HEV has been tested with both a concentric tube geometry 160
138 and a double limb circuit, and can be supplied with an adapter 161
139 to use either method. The breathing circuit can also be 162
140 equipped with humidifier or a heat and moisture exchanger 163
141 (HME) filter by choice, which is necessary to protect the 164
142 patient, who may be dehydrated, from the dry medical or 165
143 ambient air. 166

144 All equipment that comes in contact with the patient needs 167
145 to be either changed or disinfected and sterilised after every 168
146 patient. There are multiple options to do this and currently 169
147 autoclave cleaning is supported. The entire exhaust block may 170
148 be easily dismantled and swapped with a spare block, so that 171
149 the ventilator can continue to be used for the next patient 172
150 while the block undergoes steam or autoclave sterilisation. 173

151 **Control system and User Interface.** The control software is im- 174
152 plemented directly on an embedded controller, which receives 175
153 signals from the sensors and valves and fully controls the ven- 176
154 tilator operation. An ESP32 microcontroller chip has been 177
155 chosen for this function due to its high availability and low 178
156 cost. Several alternatives exist and could be used depending 179
157 on local availability in different geographical locations. 180

158 The user interface (UI) is provided via a touchscreen con- 181
159 trolled by a Raspberry Pi, which also provides WiFi and 182

154 Ethernet connection. The Raspberry Pi and embedded con- 155
156 troller are hosted on a motherboard which also provides the 156
157 interfaces to the valves and sensors, embedded sensors, LEDs 157
158 and buzzers for monitoring, and connectors to allow the pow- 158
159 ering of the fans and touchscreen. HEV can run on AC power 159
160 or an external battery, and includes a UPS which takes over 160
161 automatically if mains power is lost, allowing autonomous 161
162 operation. 162

163 All of the primary functions corresponding to the breathing 162
164 function of the patient are controlled by the microcontroller. If 163
165 the communications are interrupted, the ventilator continues 164
166 to run normally. A web server is also provided such that 165
167 display information can be seen remotely. 166

167 Following the advice of clinicians, the user interface has 167
168 been designed based on the following concepts: 168

- Respect of regulatory guidelines for included quantities. 169
- Clear text, symbols and graphs which can be seen from 170
the end of a hospital bed through PPE. 171
- Neutral colours for normal running; flashing indicators 172
and messages when there are alarms. 173
- Screen locking/unlocking feature with a timeout to pre- 174
vent accidental touchscreen presses. 175
- Confirmation required for all parameter changes (two 176
parameter changes require two separate confirmations). 177
- Set and read back information clearly displayed. 178
- Simple navigation: no setting/parameter is more than two 179
clicks away. Normal operation should be separated from 180
calibration/expert testing, to maintain an uncluttered 181
interface. 182
- Interface is touchscreen friendly: items are placed far 183
enough apart to minimise accidental mis-clicks. 184
- Familiarity: designed to look familiar to clinicians, similar 185
to already existing ventilator interfaces. 186
- Language selection is provided to increase regional adapt- 187
ability. 188

189 Two user interfaces are provided: a Native UI and a Web 189
190 UI. The Native UI runs on the touchscreen integrated into the 190
191 ventilator unit. Remote access is provided via the Web UI, 191
192 accessible via WiFi or Ethernet connection to the ventilator 192
193 on computer screens or mobile devices. In this way the data 193
194 of one or more patients can be displayed, for example, at the 194
195 nurses' station. This also opens up the possibility of remote 195
196 consulting and performance monitoring which can be very 196
197 useful for training or patient management in remote settings. 197
198 The web interface can be configured so that full control, partial 198
199 control, or no control is possible remotely. Access rights are 199
200 configurable as required and can be disabled for reasons of 200
201 security. 201

202 The Native UI is automatically displayed on power up 202
203 of the device. At start-up, the mode is selected, with set 203
204 parameters associated with that mode, which can be revisited 204
205 at any time during operation. Indicators for the power source 205
206 (mains or battery) are given on the UI, including residual 206
207 charge indicators. 207



Fig. 4. Example page displays from the Native User Interface. On the left, a typical homepage, on the right, two screens showing alarms and settings. Numbers and graphs are indicative.

Energy Physics at the University of Santiago de Compostela (IGFAE/USC) with a two-fold goal. Firstly, we wished to demonstrate that HEV could be reproduced easily in other places than CERN. Secondly, having successfully reproduced the design within a short timescale, we were able to launch additional development and contributions to the control software. In addition, this triggered discussions with local hospitals and physicians, further improving the design of the device.

Functionally, the prototype designs (Fig. 5) follow the concept described above. The resulting cabinet is mounted on wheels, can easily be moved by one person, is very stable, and provides a convenient surface to mount the display at head height. The cabinet is closed with doors, so that easy access for cleaning is possible. For safety, two compartments (front and back) provide complete separation between the pneumatic and electrical parts of the ventilator. The air tubes connect through a standard bulkhead thread connector on the outside, that make it easily replaceable to match hospital connection standards around the world.

A “homepage” is shown for the current ventilation mode with the most important settings, parameters, waveforms and control buttons (Fig. 4). Similar to the locking feature, the Native UI defaults to presenting the homepage after a period of inactivity by the user. A selection is provided for time ranges of the waveforms (i.e., showing the last 5, 15, 30 or 60 seconds). Historical data are recorded for up to 10 days. Encryption is an option for stored patient data. Settings (or target values) and measured values are clearly distinguishable in the UI. The HEV Graphical User Interface is organised to respect the requirements listed in (11, 12, 14), in particular for the available information on the homepage. Alarms are displayed in an intuitive way at the top of the screen at all times. A dedicated alarm page shows a list of the last ten alarms, ordered by alarm priority, and current and historical alarms are easily distinguishable. It is possible to reset or silence alarms (for a period of time). The alarm on-screen visualisation matches the “traffic light” lamps mounted on the unit. Finally, more technical details of the internal operation and calibration of the ventilator are provided on a separate “expert” page. The aim of the prototyping was to put in place all underlying software flexibility to be able to freely implement the desired UI. Before final manufacture a full useability study will be performed in order to optimise the UI.




Fig. 6. Potential alternative mechanical designs with an identical functionality to the HEV prototypes.

3. HEV Prototyping




Fig. 5. HEV prototype showing a front (left) and back (right) view.

Alternative mechanical designs. The prototypes were built with a deliberately large form factor to allow rapid development and exchange of parts. The final HEV ergonomics may look quite different depending on the requirements in the region of deployment and the accessories included. The HEV collaboration has provided two different alternative mechanical designs to which the HEV design could be adapted to fulfill different needs, which are illustrated in Fig. 6. Option A is more compact and can be mounted on wheels or a trolley. Space is provided to support oxygen and compressed air bottles, as well as the turbine system, so that the entire system and accessories can be provided as one integrated unit, which can be desirable for certain geographical locations. Option B is a still more compact and light version, for which the weight can be further reduced and the total dimensions are comparable to existing commercial ventilators. The touch screen can be folded away for transport and the ventilator easily mounted on a trolley. Both options are identical in functionality to the HEV prototypes which have been built and tested.

Three prototypes were constructed with an identical mechanical design in order to allow work in parallel on different aspects of the design implementation. In parallel, a fourth prototype was developed at the Galician Institute of High

275 4. Prototype test results

276 **Setup.** The HEV prototype is tested by connecting it to a
 277 lung simulator through a coaxial breathing circuit set. The
 278 coaxial breathing circuit set[†] has a differential pressure based
 279 flow sensor[‡] whose readout is embedded in HEV (`dP_patient`).
 280 Alternatives to this sensor are available with other manufac-
 281 turers[§], and a specific breathing circuit for HEV in order to
 282 decrease reliance on the existing supply chain can also be an
 283 option. The lung simulator is a TestChest light[¶] (15), which
 284 allows mechanical parameters of the lung to be changed (e.g.
 285 resistance of the airways, compliance of the lung) as well
 286 as generating adjustable spontaneous breathing and effects
 287 such as patient heartbeat. The setup is equivalent to the
 288 MHRA (14) and ISO 80601-2-12 Fig. 201.102 (16).

289 **Target Pressure Performance.** As discussed in Section 2, when
 290 the inhale starts, the proportional valve `valve_inhale` opens
 291 in a controlled way in order to reach the target pressure in
 292 a given time. This is done through a PID controller that
 293 monitors the `P_inhale` pressure measurement as input for the
 294 inhale valve opening control. As illustrated in Fig. 7, any
 295 pressure level within the setting range can be reached and the
 296 system stays stably locked to this value with an uncertainty
 297 below 3% in most of the cases.




Fig. 7. (a) Pressurisation of a 20 cm H₂O/ml compliance, 5 cm H₂O/l/sec resistance patient with various target pressures. The inhalation time is set to 1.5 seconds, and is followed by a pause of 0.5 seconds. (b) Deviation of the inhale pressure from the target as computed during the pause.

298 The performance was checked using the leak settings avail-
 299 able with TestChest and even with the highest leak setting,
 300 no difference in the pressure profile is visible.

301 Thanks to the flexibility provided by the PID control, the
 302 time needed to reach the maximum of pressurisation can be
 303 tuned between the fastest setting of about 50 ms up to about
 304 300 ms, as illustrated in Fig. 8. This gives the clinician the
 305 possibility to use the fastest response of the ventilator, typically
 306 for intubated, sedated patients, through to slower rise times
 307 which may be useful at other periods of recovery.

308 The response of the HEV ventilator to lungs with compli-
 309 ance varying from 10 to 100 ml/cm H₂O and with resistance
 310 from 5 to 50 cm H₂O/l/s has been studied. The PEEP val-
 311 ues range from 5 to 15 cm H₂O and target pressure up to
 312 45 cm H₂O were tested. A sub-sample of the pressure, flow
 313 and volume curves are reported in Fig. 9.




Fig. 8. Rising edge of the inhalation for various rise time settings. The lung compliance here is 50 ml/cm H₂O for a resistance of 5 cm H₂O/l/s.




Fig. 9. Pressure, flow and volume registered for four different patient configurations to illustrate the performance of the ventilator with the lowest and highest lung compliance, together with the lowest and highest airway resistance. The ventilator copes correctly with all conditions, showing, as expected, a more peaked flow, as the compliance and resistance is reduced.

314 When the patients show no airway resistance or when their
 315 lung compliance is low enough, the flow can fully develop
 316 during the allocated inhalation time so that the tidal volume
 317 can be computed from the product of the compliance and the
 318 differential pressure. As expected, higher resistances naturally
 319 slow down the rise of the inspiratory pressure (at the airways).
 320 Lung compliances lower than 10 cm H₂O/ml could not be
 321 tested with this lung simulator but will be the subject of a
 322 dedicated test later; extrapolating from the current results we
 323 expect a consistently good performance.

324 **Inhale Trigger Performance.** The inhale and exhale triggers are
 325 essential to guarantee the comfort of the patients and to ensure
 326 fast recovery time. The trigger functionalities were developed
 327 with this aspect in mind and particular effort was made to
 328 qualify them.

[†]Hamilton PN 260128.

[‡]Hamilton PN 281637.

[§]Intersurgical P/N 2072000

[¶]Organis GMBH, Landquart, www.organis-gmbh.com

Inhale trigger algorithm description. Whenever the patient initiates a breath, the proximal flow sensor detects an increased flow and a drop in pressure. The increase in flow is used as a trigger for the inhale sequence. The inhale trigger algorithm works in the following way. Whenever the flow reaches 10% of the maximum exhale flow, the window allowing for an inhale trigger is opened. This condition is by definition always met when the patient initiates an inhalation. The expected flow at a given instant is computed by a linear regression from a given time window before that point. It provides the baseline, to which the measured flow is compared. If the measured flow, corrected for the baseline, is above a threshold that can range from 0.2 l/min to 20 l/min, then the inhalation starts. Lower thresholds are sensitive to noise, in particular that induced by the heart-lung interactions. This threshold is set by the clinician. Other means of triggering such as a pressure-based trigger can be easily incorporated using the modular software design.




Fig. 10. Measured parameters to qualify the inhalation trigger. The variables used in this work are based on the work presented in (17) and (18).

Inhale trigger qualification. To qualify the performance of the inhale trigger, the variables defined in (17) are used. Figure 10 illustrates those variables: the Time to Minimum Pressure (TPM) is defined as the time between the beginning of the inhalation effort and the minimum value measured by P_{patient} , and the Trigger Delay Time (TDT) is defined as the time between the beginning of the inhalation effort and the moment the pressure returns to zero. Values of TPM in commercial ventilators typically vary between 50 and 150 ms depending on the inhalation effort, see for example (17), while TDT, which should ideally be below 150 ms so as not to be felt by the patient, varies for commercial ventilators in practice between 90 and 250 ms (17). The pressure-time product during trigger (PTP) is represented in Fig. 10 by the grey area and represents the effort until the pressure is effective. It ranges from 0.02 to 0.3 $\text{cm H}_2\text{O}\cdot\text{s}$ in commercial ventilators (17). The ideal PTP300 (PTP500) percentage is the ratio of the pressure integral over the 300 ms (500 ms) following the trigger delay (the area of the green regions in Fig. 10) and the ideal PTP at 300 (500) ms. It should be as large as possible, with typical commercial ventilators exhibiting values between 10 and 50% (20 and 75%) for PTP300 (PTP500) depending on the inhalation effort (17).

To test the inhalation trigger, the same lung parameters, pressurisation parameters and inhalatory effort as in (17) were used. TestChest was set with a compliance of 50 $\text{cm H}_2\text{O}/\text{ml}$ and a resistance of 5 $\text{cm H}_2\text{O}/\text{l/s}$, breath cycles at 12 respira-

	Small effort $P_{0.1}=2[\text{cm H}_2\text{O}]$			Large Effort $P_{0.1}=4[\text{cm H}_2\text{O}]$		
	10	15	20	10	15	20
ΔP [cm H ₂ O]	10	15	20	10	15	20
TPM [ms] $\pm 5\text{ms}$	110	101	76	106	82	73
TDT [ms] $\pm 5\text{ms}$	134	108	99	142	106	97
PD [cm H ₂ O] $\pm 0.2 \text{ cm H}_2\text{O}$	1.9	1.9	1.6	4.4	3.8	3.3
PTP [cm H ₂ O.s] $\pm 0.01 \text{ cm H}_2\text{O}\cdot\text{s}$	0.11	0.06	0.05	0.26	0.18	0.15
PTP300 [%] $\pm 2\%$	29	40	45	27	37	42
PTP500 [%] $\pm 1\%$	41	52	57	36	44	51

Table 1. Results of the inhale trigger characterisation. The results of the two PEEP settings (0 and 5 $\text{cm H}_2\text{O}$) are averaged in the table. The typical measurement error of each variable is reported next to the variable name.

tions per minute consisted in a 1 s inhalation with a constant inhalation flow giving an occlusion pressure at 100 ms ($P_{0.1}$) of 2 $\text{cm H}_2\text{O}$ (low effort) and 4 $\text{cm H}_2\text{O}$ (high effort) and several pressurisation parameters: ΔP of 10, 15 and 20 $\text{cm H}_2\text{O}$ with a PEEP of 0 and 5 $\text{cm H}_2\text{O}$. The inhale trigger threshold was set to 0.5 L/min.

Table 1 summarises the results of the inhale trigger qualification. The results of the two PEEP values are within errors such that they are averaged in the table. Comparing the results to the ventilator studied in (17), the HEV inhale trigger appears to perform very well.

The trigger response is studied again in the presence of leaks. Only one set of pressurisation is used, with PEEP at 0 $\text{cm H}_2\text{O}$ and $\Delta P=20 \text{ cm H}_2\text{O}$. Four settings are examined: no leaks, weak, medium and strong leaks as set by TestChest. All results are well within 10%.

Exhale trigger algorithm description. The implementation of the exhale trigger is more straightforward. When the inhale flow decreases down to a fraction of the maximum inhale flow, the exhale phase is triggered.


Exhale trigger qualification. In order to qualify the performance of the exhale trigger, the time $T_{\text{I}_{\text{ex}}}$ defined as the duration of pressurisation by the ventilator in excess with respect to T_{I} , which represents the true duration of inhalation by the patient, is measured as in (18). This is illustrated in Fig. 10. It is not a property of the ventilator per se, but by appropriate tuning of the exhale trigger it should be possible to bring it down to below 100 ms. Values of $T_{\text{I}_{\text{ex}}}$ below 10 ms are achieved.

Oxygen mixing test. Because the mixing is performed in the buffer in a phase which is physically uncorrelated to the patient breath cycle (i.e. during patient exhalation when the buffer is disconnected from the patient), we perform the mixing test independently from the test of the ventilator modes.

The O_2 concentration in the buffer is controlled by changing the relative opening time of $\text{valve}_{\text{O}_2_{\text{in}}}$ and $\text{valve}_{\text{Air}_{\text{in}}}$. For a given O_2 concentration setting, the opening times can be computed. After stabilisation of the measured O_2 concentration (FIO_2) in the lung simulator, the FIO_2 is compared to the set value. Further control will be introduced in the future by regulating the opening time from a feedback of the measured O_2 concentration in the buffer.

The measured FIO_2 as function of the expected O_2 percentage as calculated from the relative time opening of

417 valve_O₂_in and valve_Air_in is shown in Fig. 11. The
 418 measured FIO₂ in the lung is within 5% of the set value,
 419 which is an acceptable performance. Further tuning to the
 420 valve opening time can be done in order to correct for the
 421 small non-linearity in the response.



422 **Fig. 11.** Measured FIO₂ as function of the expected O₂ percentage as calculated
 423 from the relative time opening of valve_O₂_in and valve_Air_in. The grey band
 424 represents the region within $\pm 5\%$ of the set value.

422 5. Conclusions

423 HEV has been developed to be a high-quality, low-cost ven-
 424 tilator, suitable for use in a hospital setting. The design is
 425 intended for easy and fast manufacturing that can be per-
 426 formed in a decentralised way with affordable and readily
 427 available parts. The central concept of the design with a gas
 428 accumulator gives many advantages in terms of robustness,
 429 safety, affordability and precise ventilation behaviour. The
 430 electrical design is conceived in a modular way for quick pro-
 431 totyping and deployment, which facilitates mass production.
 432 The design is intended to be robust and adaptable for a wide
 433 range of geographical deployment, including in regions where
 434 compressed air may not be readily available and a turbine
 435 alternative can be used. Three prototypes have been manufac-
 436 tured and have been tested in situ under clinical supervision
 437 with the full range of simulated patients defined in the MHRA
 438 specifications and the results are presented in this paper. HEV
 439 has also been tested at the ETH Zurich Chair of Product
 440 Development and Engineering Design Ventilator test rig. In
 441 pressure control mode HEV accurately achieves the target
 442 pressures, with fast rise time which is tuneable to slower times
 443 on clinician request. Special attention has been paid to the
 444 inhale and exhale triggers to optimise patient comfort. The
 445 inhale trigger, based on the flow measurement, accurately
 446 reacts to the patient effort, with short rise times and excel-
 447 lent PTP values. The system displays and monitoring use
 448 concepts familiar to particle physics such as the possibility
 449 for remote monitoring from screens or mobile devices, data
 450 logging for quality control and performance monitoring, and
 451 remote training.

452 As far as production is concerned, it is foreseen, on the one
 453 hand, to enable this through providing partner academic insti-
 454 tutions with the detailed design for these institutions to follow
 455 up in accordance with local possibilities and standards; on the
 456 other hand, directly through industry, non-governmental, gov-
 457 ernmental and international organizations, such as the World
 458 Health Organisation (WHO), for which purpose discussions

459 are ongoing and contacts have been established with potential
 460 partners. Every effort is being made to finalise the design of
 461 the HEV in accordance with the state-of-the-art best practices
 462 and standards, but the formal certification process should of
 463 course be initiated by the parties that decide to place this
 464 device on the market. The hardware and software design has
 465 been done in a flexible way which allows the development
 466 of different modes of operation, for instance volume control
 467 modes which in principle can be developed and applied as a
 468 firmware update. In addition, the HEV prototypes can be used
 469 as a testbench to quickly implement and test novel algorithms
 470 or hardware updates, and in this way could provide a fresh
 471 avenue for medical research.

472 **ACKNOWLEDGMENTS.** We express our gratitude to Giovanni
 473 Anelli, Amy Bilton, Paola Catapano, Manuela Cirilli, Paolo Chig-
 474 giato, Beniamino Di Girolamo, Doris Forkel-Wirth, Benjamin Frisch,
 475 Samuel Herzog, Lucie Pocha, Javier Serrano, Erik Van Der Bij, Jens
 476 Vigen and Maarten Wilbers from CERN, Geneva, Switzerland, the
 477 CERN against COVID-19 task force, and to Simon Cohen from
 478 Monash Children’s Hospital, Melbourne, Australia, for many illumi-
 479 nating discussions and much practical support.

480 We acknowledge support from CERN and from the national
 481 agencies: CAPES, CNPq, FAPERJ and FINEP (Brazil); MOST
 482 and NSFC (China); CNRS/IN2P3 (France); BMBF, DFG and
 483 MPG (Germany); INFN (Italy); NWO (Netherlands); MNiSW and
 484 NCN (Poland); MEN/IFA (Romania); MSHE (Russia); MinECo
 485 (Spain); SNSF and SER (Switzerland); NASU (Ukraine); STFC
 486 (United Kingdom); DOE NP and NSF (USA). We acknowledge the
 487 computing resources that are provided by CERN, IN2P3 (France),
 488 KIT and DESY (Germany), INFN (Italy), SURF (Netherlands),
 489 PIC (Spain), GridPP (United Kingdom), RRCKI and Yandex LLC
 490 (Russia), CSCS (Switzerland), IFINHH (Romania), CBPF (Brazil),
 491 PL-GRID (Poland) and OSC (USA). We are indebted to the commu-
 492 nities behind the multiple open-source software packages on which
 493 we depend. Individual groups or members have received support
 494 from AvH Foundation (Germany); EPLANET, Marie Skłodowska-
 495 Curie Actions and ERC (European Union); A*MIDEX, ANR, Labex
 496 P2IO and OCEVU, and Région Auvergne-Rhône-Alpes (France);
 497 Key Research Program of Frontier Sciences of CAS, CAS PIFI, and
 498 the Thousand Talents Program (China); RFBR, RSF and Yandex
 499 LLC (Russia); GVA, XuntaGal and GENCAT (Spain); the Royal So-
 500 ciety, Ministry of Education, Science and Technology Development
 501 of the Republic of Serbia, under the project No 43011 and European
 502 Commission, WIDESPREAD-2018-3-TWINNING, grant number
 503 857558 - ELICSIR and the Leverhulme Trust (United Kingdom).
 504 The Institute for Electrical Engineering in Medicine, Lübeck, is
 505 partly supported by Drägerwerk AG & Co. KGaA, Lübeck)

- 506 1. L Rosenbaum, Facing Covid-19 in Italy – Ethics, Logistics, and Therapeutics on the Epi-
 507 demic’s Front Line. *New Engl. J. Medicine* **382**, 1873–1875 (2020) PMID: 32187459.
- 508 2. ML Ranney, V Griffith, AK Jha, Critical Supply Shortages – The Need for Ventilators and
 509 Personal Protective Equipment during the Covid-19 Pandemic. *New Engl. J. Medicine* **382**,
 510 e41 (2020).
- 511 3. M Malta, AW Rimoin, NA Hoff, SA Strathdee, The 2019-ncov pandemic in the global south:
 512 A tsunami ahead. *EClinicalMedicine* **23**, 100384 (2020).
- 513 4. E.J Emanuel, et al., Fair allocation of scarce medical resources in the time of covid-19. *New*
 514 *Engl. J. Medicine* **382**, 2049–2055 (2020).
- 515 5. JustActions, The Missing Piece. Why Continued Neglect of Pneumonia Threatens the
 516 Achievement of Health Goals., Technical report (2018).
- 517 6. HJ Zar, SA Madhi, SJ Aston, SB Gordon, Pneumonia in low and middle income countries:
 518 progress and challenges. *Thorax* **68**, 1052–1056 (2013).
- 519 7. SJ Aston, Pneumonia in the developing world: Characteristic features and approach to man-
 520 agement. *Respirology* **22**, 1276–1287 (2017).
- 521 8. J Pearce, A review of open source ventilators for covid-19 and future pandemics.
 522 *F1000Research* **2020** **9**, P218 (2020).
- 523 9. J Buytaert, et al., The HEV Ventilator Proposal. arXiv:2004.00534 (1 April 2020).
- 524 10. EU, Guidance on medical devices, active implantable medical devices and in vitro diagnostic
 525 medical devices in the COVID-19 context (2020).
- 526 11. Association for the Advancement of Medical Instrumentation, Emergency use ventilator (EUV)
 527 design guidance, revision 1.2 (2020).
- 528 12. World Health Organization, Technical specifications for invasive and non-invasive ventilators
 529 for COVID-19: Interim guidance, 15 April 2020 (2020).
- 530 13. R Inglis, E Ayebele, MJ Schultz, Optimizing respiratory management in resource-limited set-
 531 tings (2019).

- 532 14. UK Medicines and Healthcare products Regulatory Agency, MHRA Specification for Rapidly
533 Manufactured Ventilator System (RMVS), version 4.0 (2020).
- 534 15. J Brunner, *TestChest Physiological Model*. (2017).
- 535 16. International Organization for Standardization, Medical electrical equipment — Part 2-12: Partic-
536 ular requirements for basic safety and essential performance of critical care ventilators
537 (2020).
- 538 17. C Delgado, et al., Performance of the new turbine mid-level critical care ventilators. *Respir.*
539 *Care* **62**, 34–41 (2017).
- 540 18. L Vignaux, D Tassaux, P Jolliet, Performance of noninvasive ventilation modes on icu venti-
541 lators during pressure support: A bench model study. *Intensive care medicine* **33**, 1444–51
542 (2007).

DRAFT